Bee Vectoring Continues to Harness the Power of Bees with $1.6M Private Placement

Spotlight Companies |

Though most people will understandably make an effort to stay far away from bees, in reality, our lives are dependent upon a thriving bee population. As insects that are responsible for nearly one-third of the United States’ food population, individuals and companies alike begin to take notice when bee populations begin to wane, but unfortunately, that’s precisely what’s been happening in recent years. Bee Vectoring Technologies International Inc ($BEE:CA) is one such company that is dependent upon a thriving bee population.

Earlier this week, Bee Vectoring announced that the company has received $1.6 million in subscription commitments, and the company is near completion of a non-brokered private placement. The net proceeds of the offering will be used for general purposes, hiring, and EPA approvals. Furthermore, with a number of factors contributing to the declining bee population, such as environmental stress, bacteria and a lack of pollen, the agricultural market is looking for solutions that would lessen the negative impact on the bee population. Therefore, the proceeds will also fund the development of Bee Vectoring’s Ontario-based manufacturing plant that will produce the company’s organic pesticides.

Through their inoculum dispenser system, where bees are used to deliver natural biocontrol agents and fungal pathogens to flowering plants, Bee Vectoring is harnessing the power of nature to revolutionize the agricultural industry.

“Chemical pesticides lose their efficacy as the pathogens become immune to their properties, just like humans and the antibiotics. Biologicals don’t have the same issues,” said Michael Collinson, President, CEO, and Chairman of Bee Vectoring Technologies.“The BVT process is a lot less expensive, more efficient, uses substantially less product, is more environmentally friendly, and definitely represents the leading edge of where agriculture is going. BVT has the ability to “stack” multiple pathogens controls into their unique patent pending systems thereby delivering controls throughout a bloom period as opposed to spraying once or twice during the same period. Naturally perfect.”

This announcement follows the company’s recent feature on Business News Network’s Market Call Tonight. Bee Vectoring also began trading on the TSX Venture Exchange this past July.

“This is probably one of the more exciting areas inside agricultural sector right now,” said Collinson. “Pesticides are a $70 or $80 billion industry and Biologicals are growing at a rate of 18% year-over-year, making it one of the fastest growing segments in the industry. This is the area where companies are paying the most attention. The cost to deliver a new product today or develop a new pesticide is in excess of $250 million.”

The significance of Bee Vectoring’s million-dollar private placement goes beyond dollars and cents. Their mission to enable efficient and safe crop control will usher in a new generation of corporate responsibility while keeping the bee population abuzz.

To learn more about Bee Vectoring Technologies, visit

Disclosure: In the purview of Section 17(B) of the Securities Act of 1933 and in the interest of full disclosure, we call the reader's attention the fact that, Inc. may be compensated by the companies profiled in the Spotlight Companies section. The purpose of these profiles is to provide awareness of these companies to investors in the micro, small-cap and growth equity community and should not in any way come across as a recommendation to buy, sell or hold these securities. is not a registered broker, broker dealer, investment advisor, analyst, investment banker or underwriter. All profiles are based on information that is available to the public. The information contained herein should not be considered to be all-inclusive and is not guaranteed by to be free from misstatement or errors. Readers are reminded to do their own due diligence when researching any companies mentioned on this website.

DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to:


Emerging Growth

Immunovaccine Inc.

Immunovaccine Inc is clinical stage biopharmaceutical company. The Company develops products based on its proprietary vaccine enhancement platform in T cell activating therapies for cancer.

Private Markets

XY Find It

Founded by serial entrepreneur Arie Trouw, XY Findables follows a single guiding principle: customers should never lose anything important again. With over 50,000 users around the world, more than 100,000…


Trustify provides trust and safety in both the digital and physical worlds through our vast network of on-demand Private Investigators.By removing the large retainers and high hourly rates that traditional…